Name: MEDICENNA THERAPEUTICS CORP (MDNA) Stock
Brand: MEDICENNA THERAPEUTICS CORP
Rating: 5.5 (3 reviews)

MDNA.CA Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

6 days ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

13 days ago - By: Medicenna Therapeutics Corp.

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

a month ago - By: Medicenna Therapeutics Corp.

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

a month ago - By: Medicenna Therapeutics Corp.

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

a month ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Announces Participation in Upcoming Conferences

a month ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Announces Participation in Upcoming Conferences

2 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

2 months ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Results of Annual Meeting of Shareholders

2 months ago - By: Medicenna Therapeutics Corp.

Medicenna Announces Results of Annual Meeting of Shareholders

2 months ago - By: Medicenna Therapeutics Corp.

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Medicenna Therapeutics Corp.

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

4 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

4 months ago - By: Medicenna Therapeutics Corp.

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

4 months ago - By: Medicenna Therapeutics Corp.

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

5 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

5 months ago - By: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

5 months ago - By: Stocktwits - Mentions: TNMG GOSS RGBP BIXT ...

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

7 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

7 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

7 months ago - By: Medicenna Therapeutics Corp.

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

7 months ago - By: Medicenna Therapeutics Corp.

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

8 months ago - By: Medicenna Therapeutics Corp.

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

9 months ago - By: Medicenna Therapeutics Corp.